Skip to content Skip to footer
Join our LinkedIn Group and be part of the conversation on AI in life sciences
Login
Login
Close
MadeAi | ISPOR 2026 Spotlight: Evaluating the MadeAi Platform for Literature Screening of a Class II Medical Device

ISPOR 2026 Spotlight: Evaluating the MadeAi Platform for Literature Screening of a Class II Medical Device

BlogJune 9, 202678Views0Likes0Comments
What is AI-assisted literature screening for Class II medical devices? AI Literature Screening for Medical Devices is the application of artificial intelligence to identify, review, classify, and prioritize scientific literature relevant to a medical device. This reduces the manual effort required for evidence generation and regulatory review workflows. For instance, AI analyzes titles, abstracts, and…

Read More

The AI Evaluation Problem in Evidence Synthesis

The AI Evaluation Problem in Evidence Synthesis

BlogJune 3, 2026131Views0Likes0Comments
Why the Industry is Testing the Wrong Thing The life sciences industry faces a growing paradox: organizations are investing heavily in AI, yet many evaluation methods fail to measure how these systems actually perform in real-world evidence synthesis workflows. Every week, new evaluations emerge, and task forces publish guidelines. Academic papers rank AI tools. Organizations…

Read More

systematic-literature-review-process

How to Do an AI-Assisted Systematic Literature Review: A Step-by-Step Guide

BlogMay 14, 2026164Views0Likes0Comments
The Systematic Literature Review Definition: Systematic Literature Review (SLR) is a rigorous, structured, and transparent process of identifying, analyzing, and synthesizing all existing research on a clearly defined question or topic, providing a comprehensive summary and critical evaluation of the evidence. If you’ve ever tried to pull together evidence for a big research question, you’ll…

Read More

AI Agents Transform Regulatory Content

2026 Prediction #6: AI Agents Will Transform Regulatory Content into a Competitive Asset

BlogApril 28, 202688Views0Likes0Comments
Introduction: The Next Wave of Pharma Innovation In the life sciences, regulatory content has always played a critical role, yet it has rarely been treated as a strategic asset. Documents such as clinical summaries, regulatory submissions, safety reports, and evidence dossiers are essential for compliance, but they are often viewed as static outputs rather than…

Read More